Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 8 | 2024 | 563 | 0.770 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 465 | 0.680 |
Why?
|
| Pancreatic Diseases | 1 | 2013 | 13 | 0.450 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 107 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 802 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2022 | 246 | 0.300 |
Why?
|
| Abdominal Fat | 2 | 2017 | 17 | 0.280 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2015 | 58 | 0.240 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 67 | 0.220 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2022 | 57 | 0.190 |
Why?
|
| Retrospective Studies | 7 | 2024 | 2433 | 0.180 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 47 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 51 | 0.170 |
Why?
|
| Humans | 15 | 2024 | 26846 | 0.150 |
Why?
|
| Subcutaneous Fat | 2 | 2017 | 16 | 0.150 |
Why?
|
| Intra-Abdominal Fat | 2 | 2017 | 20 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 277 | 0.150 |
Why?
|
| Urogenital Abnormalities | 1 | 2017 | 4 | 0.150 |
Why?
|
| Lung | 1 | 2020 | 349 | 0.150 |
Why?
|
| Uterus | 1 | 2017 | 31 | 0.140 |
Why?
|
| Cervix Uteri | 1 | 2017 | 63 | 0.140 |
Why?
|
| Hysterectomy | 1 | 2017 | 80 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 507 | 0.130 |
Why?
|
| Female | 10 | 2024 | 14466 | 0.120 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2013 | 5 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 657 | 0.110 |
Why?
|
| Pancreatitis | 1 | 2013 | 36 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 67 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 104 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 131 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 442 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 367 | 0.090 |
Why?
|
| ROC Curve | 2 | 2022 | 139 | 0.080 |
Why?
|
| Obesity | 1 | 2014 | 650 | 0.080 |
Why?
|
| Child | 1 | 2013 | 2147 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 225 | 0.060 |
Why?
|
| Aged | 3 | 2018 | 5168 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 472 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 8 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2022 | 21 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 63 | 0.050 |
Why?
|
| Middle Aged | 3 | 2018 | 6820 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 28 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 17 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 119 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 95 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 37 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 419 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 2264 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 166 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 24 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 450 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 94 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2018 | 114 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 747 | 0.040 |
Why?
|
| Amenorrhea | 1 | 2017 | 5 | 0.040 |
Why?
|
| Pelvic Pain | 1 | 2017 | 10 | 0.040 |
Why?
|
| Vagina | 1 | 2017 | 42 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2018 | 250 | 0.040 |
Why?
|
| Abdomen | 1 | 2017 | 41 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 276 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 187 | 0.030 |
Why?
|
| Logistic Models | 1 | 2016 | 397 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 81 | 0.030 |
Why?
|
| Bevacizumab | 1 | 2014 | 93 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 106 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 213 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 298 | 0.030 |
Why?
|
| Adiposity | 1 | 2014 | 87 | 0.030 |
Why?
|
| Overweight | 1 | 2014 | 110 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2014 | 183 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 176 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2014 | 390 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 386 | 0.030 |
Why?
|
| Prognosis | 1 | 2014 | 759 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 1928 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 2957 | 0.020 |
Why?
|